首頁 > 市場調查報告書 > 製藥

基因治療學和RNAi 以基因為基之藥物開發

市場調查報告書

商品編碼

1736740

全球 CRISPR 和 Cas 基因市場規模（按類型、應用、最終用戶、區域範圍和預測）

Global CRISPR And Cas Genes Market Size By Type, By Application, By End-User, By Geographic Scope And Forecast

出版日期: 2025年05月06日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

CRISPR和Cas基因的市場規模和預測

2024 年 CRISPR 和 Cas 基因市場規模價值 29.0305 億美元，預計到 2032 年將達到 88.6198 億美元，2026 年至 2032 年的複合年成長率為 14.97%。

CRISPR（成簇規律間隔短回文重複序列）和 Cas（CRISPR 相關）基因是革命性的基因編輯工具。 CRISPR 是細菌的一種天然防禦機制，可以識別和切割外來 DNA，而 Cas 蛋白（例如 Cas9）則可作為分子剪刀進行切割。該技術已被開發用於多種生物體，可實現精確的基因序列修飾。其應用包括用於改善遺傳問題的基因治療、用於提高作物抗性和產量的農業生物技術，以及透過標靶疾病相關基因開發新型治療方法。

CRISPR 和 Cas 基因應用廣泛，前景看好。這項技術的進步有望推動個人化醫療的突破，屆時基因藥物可以根據個體的基因圖譜進行客製化，從而實現療效最大化。 CRISPR 精準度和遞送機制的創新有望擴大其在治療癌症和罕見遺傳疾病等複雜疾病方面的應用。

此外，CRISPR技術有望促進合成生物學的發展，使生產具有獨特功能的基因改造生物成為可能。倫理問題和法律體制對於塑造這些進步並確保其負責任地實施至關重要。

CRISPR 和 Cas 基因的全球市場動態

影響全球 CRISPR 和 Cas 基因市場的關鍵市場動態是：

關鍵市場促進因素

基因異常盛行率的不斷上升：基因異常盛行率的不斷上升是CRISPR和Cas基因市場的主要驅動力。世界衛生組織（WHO）報告稱，約有1萬種人類疾病本質上是一次性的。根據全球基因計畫的數據，全球有3億人患有罕見疾病，其中大多數是遺傳性疾病。如此龐大的患者族群對CRISPR等基因編輯技術的需求龐大，可用於潛在的治療。

基因組學研究投入不斷增加：隨著基因編輯技術的加速發展，CRISPR 和 Cas 基因市場也將蓬勃發展。 2016 年至 2020 年期間，美國政府將為基因組學研究投入超過 38 億美元，而英國醫學研究委員會將在 2022 年投入 2 億英鎊。這筆巨額資金正在推動創新、大規模研究以及基於 CRISPR 的藥物開發，使其成為市場成長的重要因素。

農業和食品生產領域應用不斷拓展：CRISPR 技術正在推動農業領域的突破，透過提高作物產量和培育健壯的植物品種來滿足日益成長的全球糧食需求。聯合國糧食及農業組織 (FAO) 預測，到 2050 年，農業生產力將提高 60%，CRISPR 已廣受認可。 2019 年《自然·植物》雜誌的一篇論文指出，CRISPR 編輯的作物已在 20 多個國家種植。 CRISPR 在農業領域的應用不斷拓展，有助於促進糧食安全和永續性，使其成為市場的關鍵驅動力。

主要問題

倫理擔憂：CRISPR技術的使用引發了重大的倫理擔憂，尤其是在生殖細胞編輯及其意外後果方面。編輯人類胚胎並進行可能遺傳給後代的修改，引發了人們對其可能對人類遺傳學產生長期影響的擔憂。這些倫理擔憂可能會導致監管延遲並影響公眾認知，從而降低對CRISPR解決方案的接受度和投資。

研發成本：開發和商業化基於 CRISPR 的技術需要大量的研發成本。創新、合規和臨床試驗相關的高昂成本，可能會使小型企業和研究機構難以在市場上競爭。這一高昂的成本阻礙了技術進步，並降低了基於 CRISPR 的治療方法的可及性。

生物安全風險：CRISPR 技術被濫用的可能性引發了生物安全擔憂，包括危險的基因改造和生物武器的研發。為了避免此類擔憂，必須以負責任的方式使用 CRISPR 技術，並採取適當的安全措施。解決生物安全問題對於該技術的可靠性和安全性至關重要。

主要趨勢

更高的精度和效率：近期的進展，包括Cas9的增強變體以及新型CRISPR相關系統的引入，顯著提高了CRISPR技術的精度和效率。這些進展提高了編輯的準確性，同時減少了脫靶效應，使CRISPR在治療應用上更加可靠。對更精準基因編輯的需求促進了相關研究和臨床試驗，增強了該技術治療遺傳性疾病和其他疾病的潛力。

農業生物技術的發展：CRISPR正被用於培育基因改造作物，使其具有產量、抗病和抗逆等特性。精準修改基因的能力促進了其在農業研究的應用。這一趨勢正在促進永續農業技術的發展，改善糧食安全，並在農業領域引發巨大的興趣和投資。

不斷發展的倫理和監管框架：更清晰的倫理原則和法律規範使負責任地採用 CRISPR 技術變得更加容易。隨著法規變得更加清晰，研究人員和公司對 CRISPR 的可接受用途有了更深入的了解，從而促進了其融入臨床實踐和商業產品。這一趨勢正在支持 CRISPR 市場的信任和成長。

新型 CRISPR 系統的出現：除 Cas9 之外，CRISPR/Cas12 和 CRISPR/Cas13 等新型 CRISPR 系統正在被發現和開發中。這些創新系統具有獨特的特性和應用，例如更少的脫靶效應和更佳的標靶性。對這些系統的探索正在推動創新，拓展 CRISPR 技術的潛在應用，從而支持市場的成長。

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) and Cas (CRISPR-associated) genes are revolutionary genetic editing tools. CRISPR is a natural defense mechanism in bacteria that identifies and cuts foreign DNA, while Cas proteins, such as Cas9, operate as molecular scissors to perform these cuts. This technique has been developed for application in a wide range of organisms, allowing for precise genetic sequence modifications. Gene therapy to rectify genetic problems, agricultural biotechnology to improve crop resistance and productivity, and the creation of novel treatments by targeting disease-associated genes are among the various uses.

The CRISPR and Cas genes are extensive and promising. Advances in this technique are likely to lead to breakthroughs in personalized medicine, with genetic medicines customized to individual genetic profiles for maximum efficacy. Innovations in CRISPR precision and delivery mechanisms are likely to expand its use in the treatment of complicated diseases such as cancer and rare genetic abnormalities.

Furthermore, CRISPR technology is expected to propel advances in synthetic biology, allowing the production of modified creatures with unique functions. Ethical issues and legal frameworks will be critical in directing these advancements and guaranteeing their responsible implementation.

Global CRISPR And Cas Genes Market Dynamics

The key market dynamics that are shaping the global CRISPR And Cas Genes Market include:

Key Market Drivers:

Increasing Prevalence of Genetic Disorders: The increasing prevalence of genetic abnormalities is a primary driver of the CRISPR And Cas Genes Market. The World Health Organization (WHO) reports that roughly 10,000 human disorders are monogenic. According to the Global Genes Project, 300 million people worldwide suffer from rare diseases, the majority of which are hereditary. This large patient population generates a high demand for gene-editing technologies such as CRISPR for possible treatments.

Rising Investments in Genomics Research: The CRISPR And Cas Genes Market forward by speeding advances in gene-editing technologies. From 2016 to 2020, the US government financed more than $3.8 billion on genomics research, with the UK's Medical Research Council committing £200 million in 2022. This enormous funding promotes innovation, large-scale studies, and the development of CRISPR-based medicines, making it an essential factor in market growth.

Expanding Applications in Agriculture and Food Production: CRISPR technology is driving breakthroughs in agriculture by boosting crop yields and developing robust plant varieties to fulfill rising global food demand. With the Food and Agriculture Organization (FAO) anticipating a 60% increase in agricultural productivity by 2050, CRISPR is being extensively embraced, as indicated by a 2019 article in Nature Plants, which found CRISPR-edited crops grown in over 20 nations. This growing application of CRISPR in agriculture promotes food security and sustainability, making it an important driver in the market.

Key Challenges:

Ethical Concerns: The use of CRISPR technology presents significant ethical concerns, notably about germline editing and its unintended consequences. Editing human embryos or making alterations that may be inherited by future generations raises concerns about the implications over time for human genetics. These ethical considerations can cause regulatory delays and influence public perception, reducing acceptance and investment in CRISPR-based solutions.

Cost of Research and Development: Developing and commercializing CRISPR-based technologies incurs enormous R&D costs. The high costs associated with innovation, regulatory compliance, and clinical trials can make it difficult for smaller enterprises and research institutes to compete in the market. This costly hurdle hinders progress and reduces the availability of CRISPR-based therapies.

Biosecurity Risks: The possible misuse of CRISPR technology raises biosecurity concerns, such as the development of risky genetic changes or bioweapons. To avoid these concerns, CRISPR technology must be utilized responsibly and with proper protections in place. Addressing biosecurity concerns is critical for the technology's credibility and safe use.

Key Trends:

Precision and Efficiency Advancements: Recent developments, including enhancements in Cas9 variations and the introduction of new CRISPR-associated systems, have considerably improved CRISPR technology's precision and efficiency. These developments lessen off-target effects while increasing editing accuracy, making CRISPR more trustworthy for therapeutic applications. The desire for more precise gene editing is fueling research and clinical trials, increasing the technology's promise for treating genetic abnormalities and other diseases.

Growth in Agricultural Biotechnology: CRISPR is being used to generate genetically modified crops with enhanced features such as increased yield, disease resistance, and stress tolerance. The technology's capacity to make precise genetic changes is pushing its use in agricultural research. This trend promotes sustainable farming techniques and improves food security, generating major interest and investment in the agriculture sector.

Advancement in Ethical and Regulatory Frameworks: Clearer ethical principles and regulatory frameworks are making it easier to employ CRISPR technology responsibly. As rules become more defined, researchers and businesses acquire a greater understanding of the acceptable use of CRISPR, facilitating its integration into clinical practice and commercial products. This tendency is boosting confidence and growth in the CRISPR market.

Emergence of Novel CRISPR Systems: The discovery and development of novel CRISPR systems beyond Cas9, such as CRISPR/Cas12 and CRISPR/Cas13, is ongoing. These innovative systems have distinct traits and applications, including fewer off-target impacts and increased targeting capabilities. Exploration of these systems drives innovation and broadens the possible applications of CRISPR technology, hence supporting market growth.

Global CRISPR And Cas Genes Market Regional Analysis

Here is a more detailed regional analysis of the global CRISPR And Cas Genes Market:

North America:

North America remains a dominant player in the CRISPR And Cas Genes Market, owing to its strong research infrastructure and advanced biotechnology sector. The region's best research institutes and universities are critical to CRISPR innovation, with NIH funding increasing from USD 5.1 Million in 2011 to more than USD 603 Million in 2020, representing an unparalleled 11,725% growth. This flood of funding has resulted in a 27% annual increase in CRISPR-related publications from North American institutions, as reported by PubMed in 2022. Complementing this, North America's well-established biotechnology industry, which includes over 6,500 biotech firms in the United States, with around 12% focusing on gene editing, drives significant progress.

The region's favorable regulatory framework also helps to advance CRISPR research and commercialization. The FDA has accepted 23 Investigational New Drug (IND) applications for CRISPR-based therapies as of 2024, a 53% increase over 2020. Since 2019, the Regenerative Medicine Advanced Therapy (RMAT) designation has advanced the approval of five CRISPR-based therapeutics.

The growing number of active CRISPR-related clinical trials, which will reach 152 in North America by September 2024, a 36% increase over the previous year, illustrates CRISPR's expanding therapeutic applicability, notably in oncology. These factors contribute to North America's leadership and continuous innovation in the CRISPR And Cas Genes Market.

Asia Pacific:

The CRISPR And Cas Genes Market in Asia Pacific is expanding rapidly, owing to significant investments, increased research activity, and a big population base. Governments in the area are making considerable expenditures in biotechnology and healthcare, with biotechnology investments increasing by 32% between 2018 and 2022, according to the Asia Pacific Economic Cooperation. China has committed USD 9.2 Billion to its precision medicine project, which includes significant funding for CRISPR technology, while Japan's genome editing consumption has increased by 41% between 2019 and 2024. This funding backing has sped up the development of CRISPR-based solutions and technologies.

The Asia Pacific area has strong financial backing, vigorous research activity, and a large population, all of which fuel demand for CRISPR applications. Research institutes have dramatically boosted their contributions to CRISPR investigations, with Asia Pacific publications increasing by 28% annually between 2018 and 2022. The region's massive population, predicted to reach 4.7 billion by 2025, opens up numerous prospects for CRISPR in healthcare and agriculture. For instance, 12 Asian countries are developing CRISPR-edited crops, with field trials increasing by 45% between 2020 and 2024. The number of CRISPR-related clinical trials in Asia Pacific increased by 140% between 2019 and 2024, demonstrating the region's growing importance in worldwide CRISPR breakthroughs and applications.

Global CRISPR And Cas Genes Market: Segmentation Analysis

The Global CRISPR And Cas Genes Market is Segmented on the basis of Type, Application, End-User, And Geography.

CRISPR And Cas Genes Market, By Type

DNA-Free Cas
Vector-Based Cas

Based on Type, the market is bifurcated into DNA-free Cas and Vector-based Cas. The CRISPR and Cas gene market is currently dominated by vector-based Cas systems, which use viral vectors to deliver the Cas gene to cells. This method has been widely utilized due to its effectiveness and versatility. DNA-free Cas systems, which use non-viral delivery techniques, are becoming the most rapidly developing sector. These systems have advantages such as fewer off-target effects and larger safety, making them appealing for therapeutic applications. As research and development in DNA-free Cas delivery progresses, it is projected to capture considerable market share in the years ahead.

CRISPR And Cas Genes Market, By Application

Genome Engineering
Functional Genomics
Disease Models

Based on Application, the market is segmented into Genome Engineering, Functional Genomics, and Disease Models. The CRISPR And Cas Genes Market is currently dominated by genome engineering applications, which include changing organisms' genetic code for a variety of reasons. This segment has grown significantly due to its ability to solve a wide range of difficulties, such as disease treatment, crop improvement, and biofuel generation. Functional genomics, which examines gene function and connections, is emerging as the most rapidly increasing segment. As researchers develop a better grasp of gene biology, functional genomics applications grow, increasing demand for CRISPR-based tools and techniques.

CRISPR And Cas Genes Market, By End-User

Biotechnology & Pharmaceutical Companies
Academic & Government Research Institutes
Contract Research Organizations

Based on End-User, the market is segmented into Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes, and Contract Research Organizations. Biotechnology and pharmaceutical businesses now dominate the CRISPR and Cas gene market, using this technology for drug discovery, development, and therapeutic applications. These firms have significant resources and competence in translating CRISPR research into commercial goods. Academic institutions and government research institutes are emerging as the most rapidly rising area. These institutions play an important role in fundamental research, promoting innovation, and improving the area of CRISPR. Their findings are frequently used to develop commercial applications, making them important contributors to market growth.

Key Players

The "Global CRISPR And Cas Genes Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are OriGene Technologies, Inc., Thermo Fisher Scientific, Takara Bio, Inc., Horizon Discovery Ltd., Addgene, Merck KGaA, Caribou Biosciences, Inc., CRISPR therapeutics, Editas Medicine and Mirus Bio LLC. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

CRISPR And Cas Genes Market Recent Developments
In June 2024, DNA nanobots, a biotechnology business, stated that it completed gene editing technology developed at the University of California (UC) Berkeley. The licensed intellectual property allows for the folding of genes into their own delivery devices, in conjunction with CRISPR-Cas, to provide very efficient non-viral gene delivery.
In April 2024, Caszyme, a biotech company based in Lithuania that develops CRISPR gene-editing technology, plans to construct a new facility. The expansion seeks to help create non-complementary competencies to fulfill the growing demand for gene-editing-based systems and products across Asia, Europe, and the United States.
In November 2022, Researchers at the Massachusetts Institute of Technology developed PASTE, a new CRISPR-based technology that inserts huge DNA sequences at targeted places in cells. The approach has the potential to treat a wide range of diseases caused by defective genes.

1 INTRODUCTION OF GLOBAL CRISPR AND CAS GENES MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

2.1 Data mining
2.2 Secondary research
2.3 Primary research
2.4 Subject matter expert advice
2.5 Quality check
2.6 Final review
2.7 Data triangulation
2.8 Bottom-up approach
2.9 Top-down approach
2.10 Research flow
2.11 Data sources

3 EXECUTIVE SUMMARY

3.1 Overview
3.2 Absolute $ Opportunity
3.3 Market attractiveness
3.4 Future Market Opportunities

4 GLOBAL CRISPR AND CAS GENES MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL CRISPR AND CAS GENES MARKET, BY TYPE

5.1 Overview
5.2 DNA-free Cas
5.3 Vector-based Cas

6 GLOBAL CRISPR AND CAS GENES MARKET, BY APPLICATION

6.1 Overview
6.2 Genome Engineering
6.3 Functional Genomics
6.4 Disease Models
6.5 Others

7 GLOBAL CRISPR AND CAS GENES MARKET, BY END-USER

7.1 Overview
7.2 Biotechnology & Pharmaceutical Companies
7.3 Academic & Government Research Institutes
7.4 Contract Research Organizations

8 GLOBAL CRISPR AND CAS GENES MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East and Africa

9 GLOBAL CRISPR AND CAS GENES MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies
9.4 Company Regional Footprint
9.5 Company Industry Footprint
9.6 ACE Matrix

10 COMPANY PROFILES

10.1 OriGene Technologies, Inc
- 10.1.1 Company Overview
- 10.1.2 Company Insights
- 10.1.3 Business Breakdown
- 10.1.4 Product Benchmarking
- 10.1.5 Key Developments
- 10.1.6 Winning Imperatives
- 10.1.7 Current Focus & Strategies
- 10.1.8 Threat from Competition
- 10.1.9 SWOT Analysis
10.2 Thermo Fisher Scientific
- 10.2.1 Company Overview
- 10.2.2 Company Insights
- 10.2.3 Business Breakdown
- 10.2.4 Product Benchmarking
- 10.2.5 Key Developments
- 10.2.6 Winning Imperatives
- 10.2.7 Current Focus & Strategies
- 10.2.8 Threat from Competition
- 10.2.9 SWOT Analysis
10.3 Takara Bio Inc.
- 10.3.1 Company Overview
- 10.3.2 Company Insights
- 10.3.3 Business Breakdown
- 10.3.4 Product Benchmarking
- 10.3.5 Key Developments
- 10.3.6 Winning Imperatives
- 10.3.7 Current Focus & Strategies
- 10.3.8 Threat from Competition
- 10.3.9 SWOT Analysis
10.4 Horizon Discovery Ltd.
- 10.4.1 Company Overview
- 10.4.2 Company Insights
- 10.4.3 Business Breakdown
- 10.4.4 Product Benchmarking
- 10.4.5 Key Developments
- 10.4.6 Winning Imperatives
- 10.4.7 Current Focus & Strategies
- 10.4.8 Threat from Competition
- 10.4.9 SWOT Analysis
10.5 Addgene
- 10.5.1 Company Overview
- 10.5.2 Company Insights
- 10.5.3 Business Breakdown
- 10.5.4 Product Benchmarking
- 10.5.5 Key Developments
- 10.5.6 Winning Imperatives
- 10.5.7 Current Focus & Strategies
- 10.5.8 Threat from Competition
- 10.5.9 SWOT Analysis
10.6 Merck KGaA
- 10.6.1 Company Overview
- 10.6.2 Company Insights
- 10.6.3 Business Breakdown
- 10.6.4 Product Benchmarking
- 10.6.5 Key Developments
- 10.6.6 Winning Imperatives
- 10.6.7 Current Focus & Strategies
- 10.6.8 Threat from Competition
- 10.6.9 SWOT Analysis
10.7 Caribou Biosciences, Inc.
- 10.7.1 Company Overview
- 10.7.2 Company Insights
- 10.7.3 Business Breakdown
- 10.7.4 Product Benchmarking
- 10.7.5 Key Developments
- 10.7.6 Winning Imperatives
- 10.7.7 Current Focus & Strategies
- 10.7.8 Threat from Competition
- 10.7.9 SWOT Analysis
10.8 CRISPR THERAPEUTICS
- 10.8.1 Company Overview
- 10.8.2 Company Insights
- 10.8.3 Business Breakdown
- 10.8.4 Product Benchmarking
- 10.8.5 Key Developments
- 10.8.6 Winning Imperatives
- 10.8.7 Current Focus & Strategies
- 10.8.8 Threat from Competition
- 10.8.9 SWOT Analysis
10.10 Editas Medicine
- 10.9.1 Company Overview
- 10.9.2 Company Insights
- 10.9.3 Business Breakdown
- 10.9.4 Product Benchmarking
- 10.9.5 Key Developments
- 10.9.6 Winning Imperatives
- 10.9.7 Current Focus & Strategies
- 10.9.8 Threat from Competition
- 10.9.9 SWOT Analysis
10.10 Mirus Bio LLC.
- 10.10.1 Company Overview
- 10.10.2 Company Insights
- 10.10.3 Business Breakdown
- 10.10.4 Product Benchmarking
- 10.10.5 Key Developments
- 10.10.6 Winning Imperatives
- 10.10.7 Current Focus & Strategies
- 10.10.8 Threat from Competition
- 10.10.9 SWOT Analysis